The Critical Role of the Host Endogenous Immune Compartment After Intracerebroventricular CAR T-Cell Therapy in Recurrent GBM
In this study, we characterized the longitudinal immune dynamics of intracerebroventricular (ICV) bivalent EGFR-IL13RA2 Chimeric Antigen Receptor (CAR) T cell therapy in patients with recurrent glioblastoma (rGBM). We performed integrated single-cell RNA sequencing (scRNA-seq) and TCR sequencing of cerebrospinal fluid (CSF), matched pre- and post-treatment tumor tissue, and CAR T cell infusion products from 18 patients enrolled in a phase I clinical trial (NCT05168423). A total of 248,834 CSF cells, 79,653 infusion product cells, and 98,809 tumor tissue cells were profiled to define cellular phenotypes, clonal dynamics, and transcriptional programs associated with therapeutic response.
CAR T cells demonstrated robust activation following infusion, peaking at Day 7 and acquiring cytotoxic and exhaustion-associated gene-expression signatures consistent with antigen engagement. However, clinical outcomes were not primarily dictated by CAR T cell kinetics or infusion product composition. Instead, therapeutic efficacy was strongly associated with remodeling of the endogenous immune compartment. Responders exhibited early, dose-dependent expansion of cytotoxic CD56dim CD16+ natural killer (NK) cells in the CSF, which correlated with improved progression-free and overall survival. In contrast, non-responders showed expansion and clonal focusing of regulatory T cells (Tregs), along with high baseline abundance of immunosuppressive “Scavenger” myeloid cells.
Together, these data identified three endogenous immune determinants of outcome-cytotoxic NK cell expansion (beneficial), Treg expansion (detrimental), and baseline suppressive myeloid programs (detrimental)-and highlight the CSF as a dynamic and informative compartment for monitoring immunotherapy response. This dataset provides a high-resolution resource for understanding response and resistance mechanisms in CAR T cell therapy for glioblastoma.
- Type: Clinical Trial
- Archive: The database of Genotypes and Phenotypes (dbGaP)
